The Valley Desk

Clinical trial reportNeuro-oncologyPublished

Phase I/II and window-of-opportunity study of pamiparib and metronomic temozolomide for recurrent isocitrate dehydrogenase mutant gliomas

Read the publication ↗ Open access copy ↗

Regional connection

Verified Author affiliations on the Europe PMC record name Perelman School of Medicine, University of Pennsylvania. Affiliation source

Publication record

Type
Clinical trial report
Venue
Neuro-oncology
Published
Subject terms
Humans; Glioma; Brain Neoplasms; Neoplasm Recurrence, Local; Isocitrate Dehydrogenase; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Prognosis; Survival Rate; Follow-Up Studies; Maximum Tolerated Dose; Mutation
PubMed ID
41099363
PubMed Central ID
PMC12979031
Added to directory
Source checked

Report a correction or request removal